Clinical Trial: A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Study Status: Completed
Recruit Status: RECRUITING
Condition: Multiple Myeloma (MM)
Study Type: INTERVENTIONAL
Official Title: A Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies (CASSANDRA)
Brief Summary:
The main aims of this 2-part study are:Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL).Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free…
Read more